Thalidomide

Generic Name
Thalidomide
Brand Names
Thalomid, Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed
Drug Type
Small Molecule
Chemical Formula
C13H10N2O4
CAS Number
50-35-1
Unique Ingredient Identifier
4Z8R6ORS6L
Background

A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence.

Indication

Thalidomide is primarily used for the acute treatment and maintenance therapy to prevent and suppress the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).

Associated Conditions
Aphthous Stomatitis, Chronic Graft-Versus-Host Disease, Erythema Nodosum Leprosum, Multiple Myeloma (MM), Primary Amyloidosis, Uremic Pruritus, Waldenström's Macroglobulinemia (WM), Moderate Erythema nodosum leprosum, Refractory Graft versus host disease, Severe Erythema nodosum leprosum, Treatment naive multiple myeloma
Associated Therapies
-
Clinical Trials
Related News

Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer

First Posted Date
2009-01-13
Last Posted Date
2024-03-04
Lead Sponsor
National Cancer Institute (NCI)
Registration Number
NCT00019539
Locations
🇺🇸

Surgery Branch, Bethesda, Maryland, United States

Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

First Posted Date
2008-11-17
Last Posted Date
2021-08-19
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
45
Registration Number
NCT00792142
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Secondary Prophylaxis of Gastrointestinal Bleeding in Cirrhotic Patients Using THALIDOMIDE

First Posted Date
2008-11-07
Last Posted Date
2013-07-31
Lead Sponsor
The Cleveland Clinic
Registration Number
NCT00787436
Locations
🇺🇸

Cleveland Clinic Foundation, Cleveland, Ohio, United States

Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis

First Posted Date
2008-10-09
Last Posted Date
2016-04-26
Lead Sponsor
Centre Hospitalier Universitaire, Amiens
Target Recruit Count
20
Registration Number
NCT00769587
Locations
🇫🇷

Centre Hospitalier Universitaire d'Amiens, Amiens, France

Low-Dose Thalidomide as Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma

First Posted Date
2008-08-05
Last Posted Date
2009-02-09
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
200
Registration Number
NCT00728078
Locations
🇨🇳

Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, China

S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

First Posted Date
2008-07-29
Last Posted Date
2015-03-06
Lead Sponsor
SWOG Cancer Research Network
Registration Number
NCT00723658
Locations
🇺🇸

Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States

🇺🇸

St. Joseph Mercy Oakland, Pontiac, Michigan, United States

🇺🇸

Sparrow Regional Cancer Center, Lansing, Michigan, United States

and more 26 locations

Thalidomide in Pediatric Inflammatory Bowel Diseases.

First Posted Date
2008-07-22
Last Posted Date
2012-10-26
Lead Sponsor
IRCCS Burlo Garofolo
Target Recruit Count
84
Registration Number
NCT00720538
Locations
🇮🇹

Department of Pediatrics, Ospedali Buzzi., Milan., Italy

🇮🇹

Department of Pediatrics, Ospedale Meyer., Florence., Florence, Italy

🇮🇹

Pediatric Gastroenterology Unit, IRCCS Gaslini., Genoa, Italy

and more 4 locations

Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma

Phase 2
Completed
Conditions
Multiple Myeloma
Interventions
Drug: Thalidomide
First Posted Date
2008-04-14
Last Posted Date
2019-10-18
Lead Sponsor
Celgene
Target Recruit Count
400
Registration Number
NCT00657488
Locations
🇧🇪

Hopital St Joseph, Gilly, Belgium

🇫🇷

Chu D'Angers - Medecine D, Angers, France

🇫🇷

Centre Hospitalier Du Dr Duschene - Hematologie, Boulogne Sur Mer, France

and more 46 locations

Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma

Phase 4
Completed
Conditions
Multiple Myeloma
Interventions
Drug: Bortezomib
Drug: Thalidomide
First Posted Date
2008-04-03
Last Posted Date
2011-09-19
Lead Sponsor
PETHEMA Foundation
Target Recruit Count
40
Registration Number
NCT00652041
Locations
🇪🇸

Hospital de la Diputación de Navarra, Navarra, Spain

🇪🇸

Hospital Morales Messeguer, Murcia, Spain

🇪🇸

Hospital La Fe, Valencia, Spain

and more 2 locations

Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma

First Posted Date
2008-03-26
Last Posted Date
2008-03-26
Lead Sponsor
Central Hospital, Nancy, France
Target Recruit Count
232
Registration Number
NCT00644306
Locations
🇫🇷

CHU Nancy - Brabois, rue du morvan, Vandoeuvre, France

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy